Irinotecan (CPT-11, Camptosar) has achieved a response rate of 23.6% in recurrent ovarian cancer. Irinotecan/cisplatin combination chemotherapy has shown a response rate of 33% in platinum-resistant ovarian cancer, and 76% when used as the initial regimen for ovarian cancer. Regarding dose-limiting toxicity, although neutropenia and diarrhea were observed, diarrhea was thought to cause no remarkable problems in the combination regimen examined. Based on these results, irinotecan is considered to be a useful drug in chemotherapy for ovarian cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
ovarian cancer
16
response rate
8
japanese ovarian
4
ovarian trials
4
trials focus
4
focus irinotecan
4
irinotecan irinotecan
4
irinotecan cpt-11
4
cpt-11 camptosar
4
camptosar achieved
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!